摘要
目的:研究沙库巴曲缬沙坦对扩张型心肌病(dilated cardiomyopathy,DCM)心力衰竭患者运动耐量及血浆嗜铬粒蛋白A(CgA)、B型利钠肽前体(NT-proBNP)水平的影响。方法:选取笔者所在医院2019年2-10月收治的80例DCM心力衰竭患者作为研究对象,采用随机数字表法将其分为治疗组和对照组,各40例。对照组采用常规药物治疗,治疗组在对照组基础上给予沙库巴曲缬沙坦治疗。比较两组临床疗效,治疗前后运动耐量、血浆CgA及NT-proBNP水平变化。结果:治疗组临床总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后两组6 min最大步行距离均较治疗前明显增加,血浆CgA、NT-proBNP水平均较治疗前明显降低,且治疗组均优于对照组,差异有统计学意义(P<0.05)。结论:沙库巴曲缬沙坦治疗DCM心力衰竭的效果显著,可有效改善患者运动耐量及心功能,降低血浆CgA、NT-proBNP水平,对临床治疗具有重要作用。
Objective:To study the effect of Sacubatril Valsartan on exercise tolerance and plasma chromogranin A(CgA),B-type natriuretic peptide precursor(NT-proBNP)levels in patients with dilated cardiomyopathy(DCM)heart failure.Method:A total of 80 patients with DCM heart failure admitted in our hospital from February to October 2019 were selected as the research objects,and were divided into the treatment group and the control group by random number table method,with 40 patients in each group.The control group was treated with conventional drugs,and the treatment group was given Sacubatril Valsartan on the basis of the control group.The clinical efficacy,changes of exercise tolerance,plasma CgA and NT-proBNP levels before and after treatment of the two groups were compared.Result:The total clinical effective rate of the treatment group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the maximum walking distance of 6 min of the two groups were significantly increased compared with those before treatment,and the plasma CgA and NT-proBNP levels were significantly decreased compared with those before treatment,and the treatment group was better than the control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Sacubatril Valsartan in the treatment of DCM heart failure is remarkable.It can effectively improve the patient’s exercise tolerance and cardiac function,reduce the levels of plasma CgA,NT-probNP,which has an important role in clinical treatment.
作者
苏瑶
程军
唐金国
刘娅
何红红
杨景涛
周倩
SU Yao;CHENG Jun;TANG Jinguo;LIU Ya;HE Honghong;YANG Jingtao;ZHOU Qian(Chongqing Yubei District People’s Hospital,Chongqing 401120,China;不详)
出处
《中外医学研究》
2020年第36期128-130,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
